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ABSTRACT — Knee pathologies including focal cartilage inju-
ries, osteoarthritis (OA), and ligament injuries are common. The 
poor regeneration and healing potential of cartilage has led to 
the search for other treatment modalities with improved heal-
ing capacity. Furthermore, with an increasing elderly popula-
tion that desires to remain active, the burden of knee pathologies 
is expected to increase. Increased sports participation and the 
desire to return to activities faster is also demanding more effec-
tive and minimally invasive treatment options. Thus, the use of 
biologic agents in the treatment of knee pathologies has emerged 
as a potential option. Despite the increasing use of biologic agents 
for knee pathology, there are confl icting results on the effi cacy of 
these products. Furthermore, strong data supporting the optimal 
preparation methods and composition for widely used biologic 
agents, such as platelet-rich plasma (PRP) and bone marrow aspi-
rate concentrate (BMAC), largely remain absent from the litera-
ture. This review presents the literature on the most commonly 
employed biologic agents for the different knee pathologies. 
■
Musculoskeletal diseases are particularly prevalent, with knee 
pathology among the most common diseases (Schiller et al. 
2012, Cross et al. 2014). These constitute both acute injuries 
and degenerative diseases including osteoarthritis (OA). Spe-
cifi cally, between 1999 and 2008 the number of total knee 
replacements due to OA in Scandinavia more than doubled 
(Robertsson et al. 2010). This translates into an annual cost of 
$462 billion dollars to the economy, secondary to lost wages 
and the costs of treatment (Mather et al. 2013). An epidemio-
logical study showed an annual incidence of 2.3 knee injuries 
per 1,000 individuals (Gage et al. 2012). Another epidemio-
logical study from Sweden reported that the incidence of knee 
injuries resulting in a visit to the Emergency Department was 
6 cases per 1,000 person years (Ferry et al. 2014).
In recent years, there has been increasing interest in the use 
of orthobiologics for the treatment of several orthopedic con-
ditions including focal cartilage injuries, early mild to moder-
ate osteoarthritis, and soft tissue injuries (LaPrade et al. 2015, 
2016, Zlotnicki et al. 2016). Orthobiologics are substances 
that are naturally found in the human body, and are used 
by orthopedic surgeons to improve the healing of cartilage, 
injured muscles, tendons, ligaments, and fractures (Samp-
son et al. 2017). These include, among others, platelet-rich 
plasma (PRP), bone marrow aspirate concentrate (BMAC), 
and cell-derived therapies. These can be injected directly into 
the injured structures such as muscle or tendon, or into the 
knee joint for intraarticular pathologies. Even without many 
clinical scientifi c studies, treatment with these agents in sports 
medicine has also advanced the use of biologic agents in the 
general population. Furthermore, there is a great desire for 
athletes to return to pre-injury levels faster, further pushing 
the use of these products. However, the cost of the develop-
ment and application of these agents is high, and both have the 
capacity to increase health care costs.
Despite the growing use of these biologic treatments, limited 
strong evidence exists either citing the effi cacy of the products 
or providing guidelines for their standard of preparation. The 
purpose of this review was to evaluate documentation on the 
effi cacy of the biologic treatments utilized in knee patholo-
gies, including platelet-rich plasma (PRP), and bone marrow 
aspirate concentrate (BMAC).
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Platelet-rich plasma (PRP) 
The use of PRP to treat sports medicine pathology of the knee 
has rapidly expanded over the past decade. Classically, PRP 
was defi ned as a volume of plasma that has a platelet count 
“above baseline” during the early stages of clinical research 
(Zhu et al. 2013). However, this defi nition has more recently 
been refi ned to be more quantitative, requiring PRP to con-
tain more than 1 million platelets per mL (Chahla et al. 2017) 
of serum or 5 times the amount of baseline platelets (Dhil-
lon et al. 2012). This elevated platelet count in PRP has been 
suggested as necessary to stimulate targeted injured cells to 
proliferate (Marx 2001, Rughetti et al. 2008). However, other 
authors reported that increased platelet concentration beyond 
the physiologic concentration did not improve functional graft 
healing in an animal model (Fleming et al. 2015). The bio-
logical mechanism driving the clinical use of PRP involves 
the action of local growth factors in PRP, which modify the 
infl ammatory response, and may affect cell proliferation and 
differentiation (LaPrade et al. 2016). 
Intra-articular PRP injections for the treatment of focal 
chondral defects and early mild to moderate osteoarthritis 
(OA) have been reported to reduce pain, while also improv-
ing range of motion and quality of life (Campbell et al. 2015) 
(Figure 1).
Despite these promising results, most of the literature has 
reported PRP to be benefi cial only for a short period of time 
(Dhillon et al. 2011). The recent systematic review by Camp-
bell et al. (2015) assessed the clinically relevant improvements 
after PRP treatment for knee osteoarthritis and found that 
intra-articular PRP injection was an effective treatment for up 
to 12 months in radiographically evaluated, early-stage OA. 
Several authors also observed a local adverse reaction, includ-
ing local swelling and regional pain after serial PRP injections 
(up to 4 injections), indicating that serial PRP injections to 
increase effect over time may not be clinically feasible. To 
evaluate the optimal leukocyte concentration in PRP, Riboh et 
al. (2016) conducted a meta-analysis on all randomized con-
trol trials (RCTs) comparing the clinical outcomes and rates 
of adverse reactions between leukocyte-poor (LP) and leu-
kocyte-rich (LR) PRP for the treatment of knee OA. 3 RCTs 
that used LP-PRP reported positive outcomes compared with 
hyaluronic acid, while only 1 RCT using LR-PRP reported 
positive effects versus hyaluronic acid (Riboh et al. 2016). 
Although several uncontrolled studies have reported pain 
reduction, functional improvement, and reduced prevalence 
of surgical revisions and arthrofi brosis (Chahla et al. 2017), 
further basic science evidence is necessary to determine the 
effects, if any, of LP- or LR-PRP for intra-articular knee treat-
ment and to evaluate whether one formulation yields superior 
results. 
In vivo anterior cruciate ligament (ACL) healing follow-
ing PRP treatment has also been studied, with some studies 
reporting improvement in ACL graft healing as measured 
mechanically or with magnetic resonance image (Radice et 
al. 2010, Vogrin et al. 2010, Cervellin et al. 2012). Conversely, 
other studies have demonstrated no benefi cial effects on ACL 
healing when examining the same parameters (Murray et al. 
2009, Nin et al. 2009). A recent systematic review of 11 ran-
domized, controlled studies examined the use of PRP in ACL 
reconstruction surgery (Figueroa et al. 2015). 6 of the 11 stud-
ies reported a faster graft maturation in the PRP group. 1 of 11 
studies reported faster healing in the PRP group when examin-
ing tunnel widening. Finally, only 1 of the 11 studies reported 
better clinical outcomes in the PRP group. 
Identifying the specifi c components of PRP which could 
be responsible for the improved clinical outcomes has been 
elusive. Some authors noted that interleukin-1 (IL-1) and epi-
dermal growth factor (EGF) stimulated meniscal stem cell 
migration, while BMP and IGF-1 stimulated fi brochondrocyte 
migration from the middle to avascular meniscal zones (Braun 
et al. 2013). An analysis of PRP treatment trends from 2010 to 
2011 indicated that 2,571 patients had received PRP injections 
in these studies, with the greatest number being treated for 
cartilage defects and meniscal injuries. Notably, PRP injec-
tion for ligamentous injuries made up only 7% of the total 
PRP utilization (Zhang et al. 2016). Despite growing use of 
PRP, there is a lack of standardized preparation protocols, and 
variability of application of PRP for the various clinical condi-
tions (Chahla et al. 2017). 
In summary, several clinical studies have reported improve-
ments in patient-reported outcomes and a signifi cant reduc-
tion in pain scores following PRP treatment in damaged tissue 
(Kon et al. 2013, Sundman et al. 2014), including tendons and 
Figure 1. Preparation of PRP. Following 1–2 spin cycles, three distinct 
layers can be identifi ed: red blood cells at the bottom, buffy coat con-
taining white blood cells and platelets in the middle, and plasma on top. 
The buffy coat is removed with a pipette and the plasma is isolated.
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early OA (Riboh et al. 2016). However, there is a paucity of 
literature with a consistently used methodology to process 
and activate these PRP formulations, making duplication of 
similar clinical results after PRP therapy or comparison of the 
effects of PRP on various musculoskeletal conditions between 
studies challenging. 
Bone marrow aspirate concentrate (BMAC)
The use of intraarticular bone marrow aspirate concentrate 
(BMAC) to treat various knee pathologies has recently grown 
in popularity because it is one of the few approaches to deliver 
progenitor cells that are currently approved by the United 
States Food and Drug Administration (FDA) and that can be 
performed in a single-stage procedure (Gobbi et al. 2015). 
For BMAC, bone marrow is harvested and centrifuged to 
isolate its cellular components in distinct layers and there-
fore it is considered to be minimally manipulated. This effec-
tively concentrates the mononucleated cells (white blood 
cells (WBCs), mesenchymal stem cells (MSCs), hematopoi-
etic stem cells (HSCs), and platelets), in one layer and the 
red blood cells in another. MSCs are of particular interest 
because they are capable of self-renewal and differentiation 
into mature muscle, bone, and cartilage (Fortier et al. 2010). 
Despite comprising only 0.001–0.01% of cells in BMAC, 
the MSCs that are present may play a role in healing through 
homing capabilities that recruit more cells to the injury site 
(Simmons and Torok–Storb 1991, Dar et al. 2005). MSCs’ 
regenerative potential, in conjunction with the ability to signal 
the surrounding tissue to secrete growth factors that modu-
late the immune response and encourage regeneration at the 
injury site, suggest that MSC presence provides BMAC with 
potentially strong regenerative properties, even for avascular 
tissues like articular cartilage. BMAC has also been reported 
to contain increased levels of interleukin 1 receptor antagonist 
(IL-1RA) and interleukin 1-beta (IL-1β), growth factors that 
have critical roles in regeneration through immune response 
modulation, in the joint space (Fortier et al. 2010, Oliver et 
al. 2015).
Several groups have demonstrated that BMAC is not only 
safe for patient use, but that it also has the potential to improve 
pain and activity level in patients with various knee patholo-
gies. Gobbi and Whyte (2016) demonstrated that, after receiv-
ing BMAC in a hyaluronic acid scaffold (HA-BMAC), all 50 
patients with grade IV chondral lesions showed signifi cantly 
improved activity and pain outcome scores at 2 years follow-
up, and each patient’s function was characterized as normal 
or nearly normal at 5 years. In comparison, the same study 
reported a decline in the percentage of patients with normal 
or nearly normal knee function from two-thirds at 2 years to 
only one-fourth at 5 years in patients who also had grade IV 
chondral lesions but who received microfracture instead of 
HA-BMAC. However, when microfracture was supplemented 
with a collagen membrane and BMAC, collagen matrix orga-
nization began to occur by 1-year follow-up in patients with 
focal chondral lesions (Enea et al. 2015).
Findings from Krych et al. (2016) support these positive 
outcomes by demonstrating that, in patients with grades III 
and IV chondral lesions who were treated with an artifi cial 
cartilage scaffold, patients receiving platelet-rich plasma 
(PRP) or BMAC in addition showed more cartilage fi ll by 
MRI after 1 year than patients who were treated with only the 
control cartilage scaffold. However, only the BMAC group 
showed MRI T2 relaxation values comparable to superfi cial 
hyaline cartilage. Similarly, 22 of 25 active patients with 
grade IV chondral lesions who received a cartilage scaffold 
supplemented with BMAC showed integration of the scaf-
fold, while 20 showed complete fi lling of their lesion by MRI 
after 3 years. 
Skowronski et al. (2013) found positive outcomes after 
treating large chondral lesions with BMAC similar to Gobbi 
and Whyte (2016), yet they also concluded that, for a simi-
lar population of patients with large chondral lesions, treat-
ment with peripheral blood rather than BMAC yielded better 
patient outcomes. A recent prospective, single-blind, placebo-
controlled pilot study also found that, in patients with bilat-
eral OA, BMAC injections provided after 6 months the same 
amount of pain relief and increased activity level as saline 
injected into the patient’s contralateral knee (Shapiro et al. 
2017). The fi ndings from this group need to be corroborated 
by data from longer-term follow-up that includes MRI visual-
ization of any changes in the cartilage structure, but these data 
suggest that we do not understand the effects that BMAC has 
on the knee. The studies cited in this review that are in favor 
of BMAC’s use in the knee largely examined the effects of 
BMAC in conjunction with a scaffold, while both Skowron-
ski et al. (2013) and Shapiro et al. (2017) found negative and 
inconclusive results after treating patients with BMAC alone. 
Thus, despite the data in support of its use for various knee 
pathologies, the fi eld requires further basic science studies to 
explain any mechanism of action, as well as strong random-
ized controlled trials.
Encouraging results have been presented also for patients 
with moderate to severe osteoarthritis (OA), demonstrating 
that BMAC injections improved functional activity scores and 
pain scores (Centeno et al. 2014). Similarly, in patients with 
chronic patellar tendinopathy, BMAC was found to signifi -
cantly improve Tegner and International Knee Documentation 
Committee (IKDC) scores 2 years post-injection (Pascual-
Garrido et al. 2012). In a systematic review, which included 
11 studies, Chahla et al. (2016) reported a lack of high-quality 
studies despite growing interest in the use of BMAC. They 
also reported that the use of BMAC was a safe procedure with 
reported good results; however, there was a varying degree of 
benefi cial results after BMAC application with and without an 
additional procedure for the treatment of chondral defects and 
early stages of osteoarthritis.
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In summary, early basic science and clinical studies have 
elucidated the benefi ts of BMAC for the treatment of knee 
pathologies in both animal and human models. The ideal 
number of BMAC treatments, the volume of treatment, and 
the timing of injections for BMAC have not been well char-
acterized. Patients with focal chondral defects who received a 
single BMAC injection have been reported to have improved 
outcomes (Gobbi et al. 2015). In patients with OA, improved 
outcomes following BMAC injections have also been 
reported; however, these studies utilized a variable number 
of treatments and had limited follow-up intervals (Hauser and 
Orlofsky 2013, Centeno et al. 2014, Kim et al. 2014). Finally, 
and most importantly, further clinical studies are needed to 
identify standardized preparation and application protocols to 
protect and help patients. 
Future directions 
Despite the increasing and widespread use of biologic treat-
ment agents in knee pathologies, there are still several areas of 
controversy and a lack of documentation. There is still no con-
sensus on the optimal protocol for preparing PRP and BMAC. 
Thus, the products termed “PRP” and “BMAC” are produced 
differently and have different compositions. It is therefore 
diffi cult to compare outcome studies and to evaluate the effi -
cacy of these agents. There is a need to standardize prepa-
ration protocols and composition of both PRP and BMAC. 
There has been increasing interest in the use of scaffolds for 
the treatment of focal chondral defects. Future research should 
also evaluate the need for scaffolds in BMAC treatment, and, 
if one is necessary, what the optimal scaffold is. Therefore, 
designing optimal scaffolds with the best mechanical and bio-
logical properties to treat focal cartilage defects needs further 
research.
Conclusions
While important advancements have been made in the fi eld 
of biologics, these therapies are still in their beginnings. In 
order to advance the knowledge, it is important to fi rst defi ne 
a minimal standard for each of these treatments and set a clear 
nomenclature system for reporting. Furthermore, due to the 
high number of variables that exists when processing these 
compounds, it is important to characterize the preparation in 
detail. While most studies suggest having good outcomes with 
a relatively safe profi le, they lack enough power and follow-
up time for the evidence to be compelling. Future randomized 
clinical trials with well-designed and defi ned protocols with 
well-defi ned controls are needed in order to elucidate the real 
effi cacy of these therapies.
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